Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Nov 28, 2017 9:36am
66 Views
Post# 27045185

RE:RE:Confusing stock pricing

RE:RE:Confusing stock pricingYes I agree with MUGMODs.
First off we need ot look at Market Cap, not just share price.
That explains a large chunk of the difference.
Secondly, don't forget their trial in 2015
"Antibe Therapeutics Suspends Its  Phase I Clinical Trial Due to Safety Concers"

That's about as bad as it can get. Very much sour taste in many mouths.
Yes those that stuck around had a chance to better understand why. 
They are able to explain the dosage was far to high plus the patient lied and had previous history of hepatitis.

Now what is a little unclear to me is that I thought I heard 2 people had elevated liver enzymes. If that is true it raises more red flags. What is also odd is that in their rat studies they gave very high dosages and that was never observed. Why? did they not check liver enzyme levels? Did it not affect Rat liver? if so then there are additional risk that obviously Rat is not a human and the effects will vary. We believe keeping the dosage low will not have this negative side effect. But this is a penny stock there is risk. Before that study there was  more unknonws but never had a safety concern. That is the second reason why market cap is so low.

Keep in mind this presents a real good opportunity, the upside is dramatically higher then it ever has been. But the risks are real and cannot be ignored. 
There can be 3 outcomes of the study:
1 - Safety Concerns brought to light
2 - No Safety Concerns but little to no GI improvement over Naproxen
3 - No safety concerns and remarkable GI improvement over Naproxen

Many people are are sitting on the sideline waiting to ensure 1&2 don't occur.
If you wait to invest after the study results, the risks are reduced dramatically. Yes the upside isn't as much but you can invest with a clear conscience.

Most investors, especially institutions are not gamblers and would rather have a little lest upside with a lot less risk. The real gap up will be if the results are postive as expected. That's when the money will be here. Not before then.

This gives us a great buying opportunity to reek massive rewards. Just be sure to do your own DD as there are risks.


Bullboard Posts